Ones To Watch News
Refine Search
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Biotechnology
Nkarta, a US biopharma developing engineered natural killer (NK) cell therapies to treat cancer, has announced the appointment of a chief medical officer (CMO). 11 January 2023
Biotechnology
Privately-held USA-based small-molecule mRNA translation specialist Anima Biotech has entered into other major collaboration, this time with US pharma major AbbVie, which is potentially worth more than $580 million and is aimed at discovering and developing drugs that modulate mRNA biology for three targets in cancer or immune disorders. 11 January 2023
Biosimilars
California, USA-based Coherus BioSciences’ shares closed up almost 10% at $9.85 yesterday, when it announced the execution of a binding term sheet with Germany’s Klinge Biopharma for the exclusive US commercialization rights to FYB203, a biosimilar candidate to Eylea (aflibercept). 11 January 2023
Biotechnology
Asklepios BioPharmaceutical, the wholly-owned but independently operated subsidiary of Bayer, has signed a multi-year research collaboration and option agreement with ReCode Therapeutics. 10 January 2023
Biotechnology
US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany’s Bayer, and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi. 10 January 2023
Biotechnology
Massachusetts, USA-based biotech Selecta Biosciences’ shares were up 11% at $1.37, after it announced an exclusive licensing and development agreement with Japan’s Astellas Pharma for IdeXork (Xork). 10 January 2023
Pharmaceutical
A UK drug discovery company has announced the appointment of a chief scientific officer (CSO). 10 January 2023
Biotechnology
Shares of Novavax closed up 11.25% at $12.26 yesterday after it announced a successor for its president and chief executive Stanley Erck, who plans to retire. 10 January 2023
Biotechnology
German drugmaker Boehringer Ingelheim and privately-held 3T Biosciences have entered into a strategic collaboration and licensing agreement to discover and develop new cancer therapies. 9 January 2023
Pharmaceutical
Anglo-Irish company Amryt Pharma has long held ambitions of following in the footsteps of Shire, the rare diseases company that was acquired by Takeda four years ago. 9 January 2023
Biotechnology
Shares of Voyager Therapeutics were up almost 30% at $9.00 pre-market this morning, as it announced a second lucrative strategic collaboration with Neurocrine Biosciences. 9 January 2023
Pharmaceutical
Privately-held Swiss drugmaker Helsinn today announced the appointment of the firm’s current chief operating officer, Dr Melanie Rolli, as group chief executive (CEO) effective from January 1, 2023. 9 January 2023
Pharmaceutical
French pharma firm Ipsen is to acquire the liver disease specialist Albireo, a company focused on the therapeutic potential of bile-acid modulators. 9 January 2023
Biotechnology
Boston, USA-based Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, has announced the completion of an $85 million financing. 9 January 2023
Biotechnology
After an active M&A year in 2022, UK pharma major AstraZeneca kicked off 2023 with an agreement to acquire USA-based clinical stage biotech CinCor Pharma. 9 January 2023
Pharmaceutical
Stalicla, a Swiss company specializing in the identification of specific phenotypes of autism spectrum disorder (ASD), has entered into an exclusive in-licensing agreement with pharma giant Novartis to develop mavoglurant (AFQ056) as a treatment for substance-use disorder and neurodevelopmental disorders (NDDs). 9 January 2023
Biotechnology
US biotech bluebird bio on Friday announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher (PRV). 7 January 2023
Biotechnology
BioRay Pharmaceutical's claim to be China’s leading autoimmune-focused biopharmaceutical firm looks substantially more robust after the company announced a $218 million strategic financing. 6 January 2023
Biotechnology
One of the pioneers of mRNA technologies, BioNTec, is investing the proceeds of its work during the pandemic on its original focus - cancer vaccines. 6 January 2023
Biotechnology
Adding to a deal with a US pharma giant last year, Cambridge, USA-based biotech Orna Therapeutics has now entered into a collaboration with Shanghai Xianbo Biotech, also known as Simnova outside of China, to discover, develop and commercialize multiple potential therapeutics in the area of oncology in China. 6 January 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze